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Nuclear spindles pave the way to metastasis
Patrick J. Hensley and Natasha Kyprianou
Compelling functional studies link nucleolar and 
spindle associated protein 1 (NUSAP1) with prostate 
cancer progression to metastasis; the findings highlight a 
new value of NUSAP1 as a biomarker of tumor recurrence 
and therapeutic targeting in pre-clinical models of 
advanced prostate cancer.
Prostate cancer accounted for an estimated 26,120 
deaths in the United States in 2016. The majority of these 
deaths occur in patients with metastatic castration-resistant 
prostate cancer (CRPC) [1]. The recognized architectural 
and genomic heterogeneity of prostate tumors and the 
persistent activation of the androgen receptor (AR) 
signaling are primarily responsible for treatment failure 
and clinical relapse [2]. Decision-making regarding the 
management of localized disease and identification of 
occult, subclinical metastasis must rely on staging and 
biomarker validation. Identification of new biomarkers 
to predict prostate cancer progression to metastasis and 
molecular signatures to define therapeutic resistance 
among patients with CRPC is an immediate and critical 
need in order to eradicate lethal disease. 
Nucleolar and spindle associated protein 1 
(NUSAP1) has been previously identified as a prognostic 
biomarker in early stage prostate cancer [3]. In the recent 
issue of Oncotarget, Gordon and colleagues interrogated 
the role of NUSAP1 in prostate cancer progression, 
using pre-clinical models and human prostate cancer 
specimens [4]. Functional studies indicate that NUSAP1 
promotes invasive and metastatic properties of prostate 
tumors, by mechanistically modulating family with 
sequence similarity 101 member B (FAM101B), a 
transforming growth factor-beta (TGF-β) signaling 
effector inducing epithelial-to-mesenchymal transition 
(EMT) and organizing the actin cytoskeleton, the scaffold 
for integration of membrane and intracellular functions. 
The findings are of translational significance enabling new 
mechanistic insights into the contribution of this nuclear 
spindle player NUSAP1 to prostate cancer cell invasion, 
as well as defining its clinical value in predicting prostate 
cancer metastasis. 
NUSAP1 is a microtubule and chromatin-binding 
protein the serves to bind DNA to the mitotic spindle and 
facilitate crosslinking of microtubules during mitosis. Its 
validation as a prostate cancer correlative marker non-
withstanding, NUSAP1 gene expression is regulated by 
a promoter binding site for the transcription factor E2F 
and negatively regulated by the tumor suppressor RB1 [3, 
5]. NUSAP1 has been causally linked to cell proliferation 
based on its role in the mitotic spindle assembly, but 
the insightful functional approaches in the current study 
provide compelling evidence on a new role for NUSAP1 
in prostate cancer invasion and metastasis. The study 
shows that loss of NUSAP1 decreased migration in 
androgen-independent prostate cancer cells but had 
limited effect on the growth dynamics of prostate cancer 
cells in vitro (proliferation, apoptosis). In vivo assessment 
of the burden of visceral and nodal metastases in the PC-3 
androgen-independent prostate cancer xenograft model, 
revealed enhanced metastases consequential to NUSAP1 
overexpression, while silencing NUSAP1 reduced 
metastasis [4]. 
Genome wide association data analysis revealed 
highest NUSAP1 transcripts in human metastatic lesions. 
Microarray analysis showed a common signature of 
transcription regulation in genes involved in cancer, 
cell injury, survival and death associated with NUSAP1 
under- or overexpression. Furthermore, validated pathway 
analysis associated this unique signature with tumor 
progression and patient survival. FAM101B (RefilinB) acts 
as a molecular switch in the organization of perinuclear 
actin during EMT [6]. EMT is recognized as a critical 
venue for epithelial derived tumors to become invasive 
and rapidly metastasize, with loss of epithelial cell 
markers and gain of mesenchymal markers at the invasive 
front. Significantly enough, FAM101B is upregulated by 
the master EMT-inducer in the prostate, TGF-β, and loss 
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Figure 1: Intracellular NUSAP1 signaling. NUSAP1 
expression is promoted by AR and E2F and inhibited by RB1. 
In the cytosol, NUSAP1 acts under the direction of TGF-β to 
organize the actin cytoskeleton and drive EMT towards invasion 
and metastasis of prostate cancer cells. NUSAP1- Nucleolar 
and spindle associated protein 1, AR- Androgen receptor, 
RB1- Retinoblastoma 1, E2F- E2 factor, FAM101B- Family 
with sequence similarity 101 member B, TGF-β- Transforming 
growth factor-beta, EMT- Epithelial-to-mesenchymal transition
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of FAM101B reversed the EMT phenotype exhibited in 
NUSAP1 overexpressing prostate cancer cells in vitro, 
pointing to the functional interaction between the two 
players [4]. 
Elucidation of downstream signaling targets/
effectors of NUSAP1 is currently under mechanistic 
pursuit with evidence so far implicating the retinoblastoma 
RB1 tumor suppressor as a leading candidate, since the 
transcriptional regulation of NUSAP1 expression is 
under the control of the well-defined E2F-RB1 pathway 
(Figure 1). Thus RB1, loss of which correlates with 
prostate cancer virulence, provides a mechanism bridging 
upregulation of NUSAP1 to the invasive properties of 
prostate cancer cells [5]. Further molecular evidence 
indicating an AR binding site upstream of the NUSAP1 
transcription start site and NUSAP1 induction in response 
to androgens in androgen-sensitive prostate cancer cells 
[7], positions the AR as a mechanistic protagonist in the 
upregulation of NUSAP1 in metastatic prostate cancer. 
Growth stimulation promotes the actin polymerization 
assembly to generate movement, via cofilin, a TGF-β 
signaling effector recruited to stabilize perinuclear and 
cytosolic actin bundles towards an EMT phenotype [8], 
thus navigating the actin cytoskeleton polymerization in 
prostate cancer cells (Figure 1). Mutational inactivation 
of cofilin, significantly compromises prostate cancer 
cell adhesion, migration and filpodia formation due to 
enhanced polymerization of F-actin filaments [8]. 
The role of NUSAP1 in regulating microtubule 
assembly and stability during mitosis, through its 
signaling effector FAM101B, provides new target leads. 
Taxane- chemotherapy is a clinically effective treatment 
for metastatic CRPC through stabilizing β-tubulin within 
the microtubule structure, deregulation of the mitotic 
spindle, apoptosis induction and impairing AR activity 
[1, 2]. Considering that therapeutic resistance leads to 
recurrent disease in CRPC patients [2], NUSAP1 presents 
itself at a convergence targeting point, calling for synergy 
in action against NUSAP1 in combination with taxane 
chemotherapy in CRPC. Support for an optimization 
platform is granted from recent evidence that taxane-
induced apoptosis in oral squamous cell carcinoma was 
enhanced in the absence of NUSAP1 [9]. 
With the knowledge that development of castration 
resistance is pivotal in the progression to aggressive 
disease, it is critical that future investigative efforts focus 
on CRPC tumors with diverse AR status that may impact 
the effects of NUSAP1 on the dynamics of microtubules 
and the actin cytoskeleton towards metastasis. The 
preclinical models used in this study were limited by their 
inability to capture and characterize the complexity of 
the tumor microenvironment during advanced metastatic 
progression [4]. Utilization of relevant models of prostate 
cancer metastasis will enable biological outcomes as 
to the impact of NUSAP1 on the EMT landscapes and 
microtubule stabilization dynamics, ultimately defining 
its therapeutic targeting value by combinatorial synergy 
of FDA approved agents with new drugs (Figure 1). 
Development of a novel inhibitor targeting NUSAP1 and 
its nuclear partners, might deliver a personalized therapy 
with a promise in the clinical management of patients with 
advanced prostate cancer.
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